CVS Health (NYSE:CVS) reported stronger-than-expected fourth-quarter revenue of $105.7 billion and adjusted earnings per share of $1.09, driven by growth across its pharmacy, health services, and insurance segments. The company also confirmed its full-year 2026 adjusted EPS guidance of $7 to $7.20, slightly above analyst estimates. CEO David Joyner highlighted progress in transforming healthcare through drug price reduction and improved navigation.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
CVS Health posts strong Q4 revenue, raises full-year guidance
CVS Health (NYSE:CVS) reported stronger-than-expected fourth-quarter revenue of $105.7 billion and adjusted earnings per share of $1.09, driven by growth across its pharmacy, health services, and insurance segments. The company also confirmed its full-year 2026 adjusted EPS guidance of $7 to $7.20, slightly above analyst estimates. CEO David Joyner highlighted progress in transforming healthcare through drug price reduction and improved navigation.